Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T ...

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor ...

VANCOUVER, British Columbia, November 07, 2024 -- ( BUSINESS WIRE )-- AbCellera (Nasdaq: ABCL) today announced new data on ...

AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...

AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...

MacMaster, Ph.D., associate professor of Microbiology-Immunology, have discovered that administering an antibody treatment ...

1 Racah Institute of Physics, The Hebrew University, Jerusalem, Israel 2 School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel T cells respond swiftly, ...

While therapeutic antibodies targeting these inhibitory receptors can sustain T cell function, recent studies have underscored the importance of positive costimulation in limiting the development of ...

Claudin-6 (CLDN6) is a tight junction protein that has been found to be up-regulated in around 20 different types of cancer, among them ovarian, endometrial and germ cell tumors. Conventional T-cell ...